10-K: Nuwellis, Inc. Details Capital Stock Structure and Anti-Takeover Measures in 10-K Filing

Nuwellis, Inc.'s 10-K filing outlines the terms of its common and preferred stock, including voting rights, dividend entitlements, and anti-takeover provisions.

Summary

• Nuwellis, Inc., a Delaware-incorporated company, details its capital stock structure in its 10-K filing.
• The company has common stock, Series F Preferred Stock, and Series J Preferred Stock.
• Common stockholders are entitled to dividends declared by the board and one vote per share, with certain voting restrictions on preferred stock amendments.
• A super-majority vote of 66 2/3% is required to alter certain provisions of the certificate of incorporation, including the number of directors, board classification, and limitations on director removal.
• Common stockholders do not have conversion, redemption, or preemptive rights.
• In liquidation, common stockholders share ratably in assets after creditors and preferred stockholders are satisfied.
• The board can issue preferred stock in series, setting voting powers, preferences, and rights.
• Series F Preferred Stock has a liquidation preference of $0.0001 per share and is convertible into common stock at a price of $25.00 as of December 31, 2022.
• The company can force conversion of Series F Preferred Stock if the common stock price exceeds 300% of the conversion price for 20 of 30 trading days and daily trading volume exceeds $200,000.
• Series F Preferred Stock has anti-dilution protection, which expires if the common stock price exceeds 300% of the conversion price for 20 of 30 trading days and daily trading volume exceeds $200,000.
• Series J Preferred Stock has a liquidation preference of $25.00 per share and pays dividends in-kind at an annual rate of 20%.
• Series J Preferred Stock is convertible into common stock at a price of $1.01 as of October 12, 2023, subject to adjustments.
• Both Series F and J Preferred Stock have beneficial ownership limitations of 4.99% or 9.99% of the outstanding common stock.
• As of December 31, 2023, there were warrants outstanding to purchase 2,963,192 shares of common stock at prices ranging from $3.30 to $189,000.
• The company is subject to anti-takeover provisions in its charter and bylaws, including a staggered board, super-majority voting requirements, and limitations on stockholder actions.
• Delaware law also restricts business combinations with interested stockholders for three years unless certain conditions are met.
• The company's certificate of incorporation designates the Delaware Court of Chancery as the exclusive forum for certain legal actions.
• The company limits director liability and provides indemnification to the fullest extent permitted by law.
• The transfer agent and registrar for the common stock is Equiniti Trust Company, LLC.
• The common stock trades on The Nasdaq Capital Market under the symbol NUWE.

Sentiment

Score: 6

Explanation: The document is factual and descriptive, with no strong positive or negative sentiment. It is a standard regulatory filing.

Positives

• The company has a clear structure for its common and preferred stock.
• The board has the authority to issue preferred stock with flexible terms.
• The Series F Preferred Stock has anti-dilution protection.
• The company has a transfer agent and registrar for its common stock.

Negatives

• Common stockholders have limited voting rights on preferred stock amendments.
• A super-majority vote is required to alter certain provisions of the certificate of incorporation.
• Common stockholders do not have conversion, redemption, or preemptive rights.
• The company is subject to anti-takeover provisions that could make it difficult to acquire.
• There is no established public trading market for the Series F or Series J Preferred Stock.

Risks

• The super-majority voting requirements could make it difficult for stockholders to influence company decisions.
• The anti-takeover provisions could discourage potential acquirers.
• The lack of a public trading market for the preferred stock could limit liquidity for those investors.
• The beneficial ownership limitations could restrict the ability of investors to convert preferred stock.
• The company's reliance on third-party suppliers for components could lead to supply chain issues.

Future Outlook

The document does not contain any specific forward-looking statements or guidance regarding future financial performance or operations.

Industry Context

This document is a standard 10-K filing, which is a routine part of a public company's reporting requirements. The details of the capital structure and anti-takeover provisions are typical for companies listed on the Nasdaq.

Comparison to Industry Standards

• The use of a staggered board and super-majority voting requirements are common anti-takeover measures used by public companies to protect against hostile takeovers, similar to companies like BioMarin Pharmaceutical Inc. and Regeneron Pharmaceuticals Inc.
• The preferred stock structure with conversion rights and liquidation preferences is a standard practice in corporate finance, similar to companies like Moderna Inc. and Novavax Inc.
• The beneficial ownership limitations are also common to prevent any single investor from gaining too much control, similar to companies like Incyte Corp. and Vertex Pharmaceuticals Inc.
• The exclusive forum provision is a common practice to limit litigation risk, similar to companies like Gilead Sciences Inc. and Amgen Inc.

Stakeholder Impact

• Shareholders should be aware of the voting restrictions and anti-takeover provisions.
• Potential investors should consider the lack of a public trading market for the preferred stock.
• Creditors should be aware of the liquidation preferences of the preferred stock.

Key Dates

Keywords

common stock, preferred stock, Series F Preferred Stock, Series J Preferred Stock, voting rights, dividends, conversion rights, anti-takeover, warrants, Delaware law, liquidation preference, super-majority vote, certificate of incorporation